A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021
ABSTRACT Background Hepatocellular carcinoma (HCC) is the second leading cause of cancer‐related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods that have quickly changed clinical guidelines and practices. Because of the high heterogeneity...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Cancer Innovation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cai2.70006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850270210591817728 |
|---|---|
| author | Hong Zhao Yilei Mao Hongguang Wang Aiping Zhou Zhengqiang Yang Yue Han Gong Li Xinyu Bi Chunyi Hao Xiaodong Wang Jun Zhou Chaoliu Dai Feng Wen Jingdong Zhang Ruibao Liu Tao Li Lei Zhao Zuoxing Niu Tianfu Wen Qiu Li Hongmei Zhang Xiaoming Chen Minshan Chen Ming Zhao Yajin Chen Jun Yu Jie Shen Xiangchen Li Lianxin Liu Zhiyong Huang Wei Zhang Feng Shen Weiping Zhou Zhengang Yuan Jian Zhai Ningling Ge Yongjun Chen Huichuan Sun Jianqiang Cai |
| author_facet | Hong Zhao Yilei Mao Hongguang Wang Aiping Zhou Zhengqiang Yang Yue Han Gong Li Xinyu Bi Chunyi Hao Xiaodong Wang Jun Zhou Chaoliu Dai Feng Wen Jingdong Zhang Ruibao Liu Tao Li Lei Zhao Zuoxing Niu Tianfu Wen Qiu Li Hongmei Zhang Xiaoming Chen Minshan Chen Ming Zhao Yajin Chen Jun Yu Jie Shen Xiangchen Li Lianxin Liu Zhiyong Huang Wei Zhang Feng Shen Weiping Zhou Zhengang Yuan Jian Zhai Ningling Ge Yongjun Chen Huichuan Sun Jianqiang Cai |
| author_sort | Hong Zhao |
| collection | DOAJ |
| description | ABSTRACT Background Hepatocellular carcinoma (HCC) is the second leading cause of cancer‐related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods that have quickly changed clinical guidelines and practices. Because of the high heterogeneity of HCC, there are still some gaps between the guidelines and real‐world clinical practice. The present study surveyed experts in China to investigate the current treatment concepts and clinical practice regarding HCC. Methods A questionnaire survey on the treatment concepts and clinical practice of HCC was administered to 310 experts with senior professional titles in 2020 and 312 experts in 2021. The results were analyzed and compared. Results For treating patients with resectable HCC, 28% of hepatobiliary surgeons indicated neoadjuvant therapy, and 7% chose systemic therapy ± locoregional therapy as 1 L therapy in 2021 compared with 20% and 1% in 2020. More experts chose adjuvant treatment within 1 month in 2021 compared with 2020, and 6 months and 12 months were the leading choices for the duration of adjuvant treatment. In 2021, 79% of surgeons and 19% of interventionalists were willing to conduct downstaging/conversion therapy for patients with potentially resectable HCC, and 78% chose tyrosine kinase inhibitors (TKI) + immunotherapy (IO) + locoregional therapy for cases in which R0 resection could not be achieved. For completely unresectable HCC, more experts preferred TKI + IO‐based therapy as 1 L therapy in 2021 compared with 2020 (78% vs. 55%). The proportion of experts who indicated TKI + IO‐based therapy as 2 L therapy increased from 32% in 2020 to 40% in 2021. Conclusion The survey results indicated that in 2021, compared with 2020, more experts opted to administer IO + TKI for the treatment of liver cancer, and more experts and patients were willing to participate in clinical research. |
| format | Article |
| id | doaj-art-573bc77cda814b98b7212507a5b7759a |
| institution | OA Journals |
| issn | 2770-9191 2770-9183 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Innovation |
| spelling | doaj-art-573bc77cda814b98b7212507a5b7759a2025-08-20T01:52:44ZengWileyCancer Innovation2770-91912770-91832025-06-0143n/an/a10.1002/cai2.70006A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021Hong Zhao0Yilei Mao1Hongguang Wang2Aiping Zhou3Zhengqiang Yang4Yue Han5Gong Li6Xinyu Bi7Chunyi Hao8Xiaodong Wang9Jun Zhou10Chaoliu Dai11Feng Wen12Jingdong Zhang13Ruibao Liu14Tao Li15Lei Zhao16Zuoxing Niu17Tianfu Wen18Qiu Li19Hongmei Zhang20Xiaoming Chen21Minshan Chen22Ming Zhao23Yajin Chen24Jun Yu25Jie Shen26Xiangchen Li27Lianxin Liu28Zhiyong Huang29Wei Zhang30Feng Shen31Weiping Zhou32Zhengang Yuan33Jian Zhai34Ningling Ge35Yongjun Chen36Huichuan Sun37Jianqiang Cai38Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital PUMC and Chinese Academy of Medical Sciences (CAMS) Beijing ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Interventional Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH) School of Clinical Medicine, Tsinghua University Beijing ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Sarcoma Center Peking University Cancer Hospital & Institute Beijing ChinaDepartments of Interventional Oncology Peking University Cancer Hospital & Institute Beijing ChinaDepartment of Medical Oncology Peking University Cancer Hospital & Institute Beijing ChinaDepartment of General Surgery Shengjing Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Radiology Shengjing Hospital of China Medical University Shenyang Liaoning ChinaMedical Oncology Department of Gastrointestinal Cancer Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University Shenyang Liaoning ChinaInterventional Radiological Department Harbin Medical University Cancer Hospital Harbin Heilongjiang ChinaDepartment of General Surgery, Qilu Hospital The Second Hospital of Shandong University Jinan Shandong ChinaDepartment of Hepatobiliary Surgery Shandong Cancer Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Science Jinan Shandong ChinaDepartment of Gastroenterology, Ward 2, Shandong Cancer Hospital and Institute Shandong First Medical University Jinan Shandong ChinaDepartment of Liver Surgery, West China Hospital Sichuan University Chengdu Sichuan ChinaCancer Center, West China Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Clinical Oncology, Xijing Hospital The Air Force Military Medical University Xi'an Shaanxi ChinaDepartment of Interventional Radiology Guangdong Provincial People's Hospital Guangzhou Guangdong ChinaDepartment of Liver Surgery Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group Sun Yat‐sen University Cancer Center Guangzhou Guangdong ChinaDepartment of Hepatobiliary Surgery, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou Guangdong ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang ChinaDepartment of Oncology The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu ChinaHepatobiliary Center The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei ChinaDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital Second Military Medical University (Naval Medical University) Shanghai ChinaDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital Second Military Medical University (Naval Medical University) Shanghai ChinaDepartment of Oncology, Eastern Hepatobiliary Surgery Hospital Second Military Medical University Shanghai ChinaDepartment II of Interventional Radiology Eastern Hepatobiliary Surgery Hospital Shanghai ChinaDepartment of Hepatic Oncology, Zhongshan Hospital, Liver Cancer Institute and Key Laboratory of Carcinogenesis and Cancer Invasion Fudan University Shanghai ChinaDepartment of General Surgery, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaABSTRACT Background Hepatocellular carcinoma (HCC) is the second leading cause of cancer‐related death in China. The rapid progress in systemic therapies has led to the approval of many therapeutic methods that have quickly changed clinical guidelines and practices. Because of the high heterogeneity of HCC, there are still some gaps between the guidelines and real‐world clinical practice. The present study surveyed experts in China to investigate the current treatment concepts and clinical practice regarding HCC. Methods A questionnaire survey on the treatment concepts and clinical practice of HCC was administered to 310 experts with senior professional titles in 2020 and 312 experts in 2021. The results were analyzed and compared. Results For treating patients with resectable HCC, 28% of hepatobiliary surgeons indicated neoadjuvant therapy, and 7% chose systemic therapy ± locoregional therapy as 1 L therapy in 2021 compared with 20% and 1% in 2020. More experts chose adjuvant treatment within 1 month in 2021 compared with 2020, and 6 months and 12 months were the leading choices for the duration of adjuvant treatment. In 2021, 79% of surgeons and 19% of interventionalists were willing to conduct downstaging/conversion therapy for patients with potentially resectable HCC, and 78% chose tyrosine kinase inhibitors (TKI) + immunotherapy (IO) + locoregional therapy for cases in which R0 resection could not be achieved. For completely unresectable HCC, more experts preferred TKI + IO‐based therapy as 1 L therapy in 2021 compared with 2020 (78% vs. 55%). The proportion of experts who indicated TKI + IO‐based therapy as 2 L therapy increased from 32% in 2020 to 40% in 2021. Conclusion The survey results indicated that in 2021, compared with 2020, more experts opted to administer IO + TKI for the treatment of liver cancer, and more experts and patients were willing to participate in clinical research.https://doi.org/10.1002/cai2.70006adjuvant therapydownstaging/conversion therapyimmunotherapyneoadjuvant therapyTKI |
| spellingShingle | Hong Zhao Yilei Mao Hongguang Wang Aiping Zhou Zhengqiang Yang Yue Han Gong Li Xinyu Bi Chunyi Hao Xiaodong Wang Jun Zhou Chaoliu Dai Feng Wen Jingdong Zhang Ruibao Liu Tao Li Lei Zhao Zuoxing Niu Tianfu Wen Qiu Li Hongmei Zhang Xiaoming Chen Minshan Chen Ming Zhao Yajin Chen Jun Yu Jie Shen Xiangchen Li Lianxin Liu Zhiyong Huang Wei Zhang Feng Shen Weiping Zhou Zhengang Yuan Jian Zhai Ningling Ge Yongjun Chen Huichuan Sun Jianqiang Cai A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 Cancer Innovation adjuvant therapy downstaging/conversion therapy immunotherapy neoadjuvant therapy TKI |
| title | A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 |
| title_full | A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 |
| title_fullStr | A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 |
| title_full_unstemmed | A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 |
| title_short | A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021 |
| title_sort | survey of clinical practices for hepatocellular carcinoma among experts at tertiary hospitals in china from 2020 to 2021 |
| topic | adjuvant therapy downstaging/conversion therapy immunotherapy neoadjuvant therapy TKI |
| url | https://doi.org/10.1002/cai2.70006 |
| work_keys_str_mv | AT hongzhao asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yileimao asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT hongguangwang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT aipingzhou asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhengqiangyang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yuehan asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT gongli asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xinyubi asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT chunyihao asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiaodongwang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT junzhou asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT chaoliudai asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT fengwen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jingdongzhang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT ruibaoliu asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT taoli asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT leizhao asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zuoxingniu asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT tianfuwen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT qiuli asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT hongmeizhang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiaomingchen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT minshanchen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT mingzhao asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yajinchen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT junyu asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jieshen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiangchenli asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT lianxinliu asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhiyonghuang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT weizhang asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT fengshen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT weipingzhou asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhengangyuan asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jianzhai asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT ninglingge asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yongjunchen asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT huichuansun asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jianqiangcai asurveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT hongzhao surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yileimao surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT hongguangwang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT aipingzhou surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhengqiangyang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yuehan surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT gongli surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xinyubi surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT chunyihao surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiaodongwang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT junzhou surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT chaoliudai surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT fengwen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jingdongzhang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT ruibaoliu surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT taoli surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT leizhao surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zuoxingniu surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT tianfuwen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT qiuli surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT hongmeizhang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiaomingchen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT minshanchen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT mingzhao surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yajinchen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT junyu surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jieshen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT xiangchenli surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT lianxinliu surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhiyonghuang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT weizhang surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT fengshen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT weipingzhou surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT zhengangyuan surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jianzhai surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT ninglingge surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT yongjunchen surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT huichuansun surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 AT jianqiangcai surveyofclinicalpracticesforhepatocellularcarcinomaamongexpertsattertiaryhospitalsinchinafrom2020to2021 |